Rheumatoide Arthritis – serologische Marker auf dem Prüfstand

Zusammenfassung

Die rheumatoide Arthritis (RA) ist bei einer Prävalenz von 1–2% die häufigste chronisch entzündliche Autoimmunerkrankung. Optimale Strategien für die Diagnose, Verlaufskontrolle und Therapieüberwachung von Patienten mit RA gewährleisten das sinnvolle, kosteneffiziente Einsetzen von Laborparameter. In der vorliegenden Übersichtsarbeit wird der Nutzen länger oder erst kürzlich eingesetzter serologischer Parameter für RA aus heutiger Sicht dargestellt.

Summary

The rheumatoid arthritis (RA) is the most common chronic inflammatory autoimmune disease, with a prevalence of 1–2%. Optimal strategies for the diagnosis and monitoring of the patients with RA allow a cost-efficient use of the laboratory markers. The following review updates on the usefulness of the currently used serological markers for RA.

Schlüsselwörter

Rheumatoide Arthritis - CCP - Zytokine - COMP

Keywords

Rheumatoid arthritis - CCP - cytokines - COMP

• Literatur

• 1 http://www.dgkl.de 2005 Ref Type: Internet Communication
• 2 http://www.gbe-bund.de 2005 Ref Type: Internet Communication
• 3 Arnett FC., Edworthy SM., Bloch DA. et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31 (03) 315-24.
• 4 Arvidson NG., Larsson A., Larsen A. Disease activity in rheumatoid arthritis: fibrinogen is superior to the erythrocyte sedimentation rate. Scand J Clin Lab Invest 2002; 62 (04) 315-9.
• 5 Bas S., Genevay S., Meyer O., Gabay C. Anticyclic citrullinated peptide antibodies, Ig M and Ig A rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 (05) 677-80.
• 6 Bas S., Perneger TV., Kunzle E., Vischer TL. Comparative study of different enzyme immunoassays for measurement of Ig M and Ig A rheumatoid factors. Ann Rheum Dis 2002; 61 (06) 505-10.
• 7 Bizzaro N., Mazzanti G., Tonutti E. et al Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47 (06) 1089-93.
• 8 Buch MH., Seto Y., Bingham SJ. et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52 (01) 42-8.
• 9 Caramaschi P., Biasi D., Tonolli E. et al Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005 Epub ahaead of print
• 10 Crnkic M., Mansson B., Larsson L. et al Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003; 5 (04) R 181-5.
• 11 de Benedetti F., Massa M., Robbioni P. et al Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34 (09) 1158-63.
• 12 De Rycke L., Peene I., Hoffman IE. et al Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63 (12) 1587-93.
• 13 Dessein PH., Joffe BI., Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004; 31 (06) 1095-7.
• 14 Felson DT., Anderson JJ., Boers M. et al American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38 (06) 727-35.
• 15 Ferucci ED., Majka DS., Parrish LA. et al Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticularonset juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52 (01) 239-46.
• 16 Firestein GS., Paine MM. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 1992; 140 (06) 1309-14.
• 17 Forslind K., Eberhardt K., Jonsson A., Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31 (09) 593-8.
• 18 Forslind K., Eberhardt K., Jonsson A., Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992; 31 (09) 593-8.
• 19 Hanemaaijer R., Koolwijk P., le Clercq L. et al Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993; 296 (Pt 3) 803-9.
• 20 Hedbom E., Antonsson P., Hjerpe A. et al Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992; 267 (09) 6132-6.
• 21 Hoffman IE., Peene I., Pottel H. et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 2005; 51 (01) 261-3.
• 22 Jonsson T., Steinsson K., Jonsson H. et al. Combined elevation of Ig M and Ig A rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Rheumatol Int 1998; 18 (03) 119-22.
• 23 Jonsson T., Valdimarsson H. What about Ig A rheumatoid factor in rheumatoid arthritis?. Ann Rheum Dis 1998; 57 (01) 63-4.
• 24 Kasapcopur O., Altun S., Aslan M. et al Diagnostic accuracy of anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63 (12) 1687-9.
• 25 Lacki JK., Samborski W., Mackiewicz S., Mackiewicz U. Do changes in clinical improvement in rheumatoid arthritis patients treated with immunosuppressive drugs reflect the changes in acute phase proteins?. Ups J Med Sci 1995; 100 (03) 233-42.
• 26 Lard LR., Roep BO., Toes RE., Huizinga TW. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol 2004; 31 (01) 35-9.
• 27 Larsson E., Mussener A., Heinegard D. et al Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. Br J Rheumatol 1997; 36 (12) 1258-61.
• 28 Lepore L., Pennesi M., Saletta S. et al. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12 (05) 561-5.
• 29 Lindqvist E., Eberhardt K., Bendtzen K. et al Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64 (02) 196-201.
• 30 Madson KL., Moore TL., Lawrence III JM., Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994; 21 (12) 2359-63.
• 31 Mangge H., Kenzian H., Gallistl S. et al Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38 (02) 211-20.
• 32 Mansson B., Carey D., Alini M. et al Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95 (03) 1071-7.
• 33 Mansson B., Carey D., Alini M. et al Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95 (03) 1071-7.
• 34 Marti C., Neidhart M., Gerber T. et al Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis. Z Rheumatol 1999; 58 (02) 79-87.
• 35 Neidhart M., Muller-Ladner U., Frey W. et al Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon run ners. Osteoarthritis Cartilage 2000; 8 (03) 222-9.
• 36 Nielen MM., van Schaardenburg D., Reesink HW. et al Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004; 50 (08) 2423-7.
• 37 Nielen MM., van Schaardenburg D., Reesink HW. et al Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50 (02) 380-6.
• 38 Ou LS., See LC., Wu CJ. et al Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002; 21 (01) 52-6.
• 39 Posthumus MD., Limburg PC., Westra J. et al. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (04) 465-72.
• 40 Rantapaa-Dahlqvist S., de Jong BA., Berglin E. et al Antibodies against cyclic citrullinated peptide and Ig A rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48 (10) 2741-9.
• 41 Raza K., Breese M., Nightingale P. et al Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32 (02) 231-8.
• 42 Rooney M., David J., Symons J., Di Giovine F. et al Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995; 34 (05) 454-60.
• 43 Roux-Lombard P., Eberhardt K., Saxne T. et al Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 2001; 40 (05) 544-51.
• 44 Saxne T., Heinegard D. Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. Arthritis Rheum 1995; 38 (02) 294-6.
• 45 Schellekens GA., de Jong BA., van den Hoogen FH. et al Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101 (01) 273-81.
• 46 Schellekens GA., Visser H., de Jong BA. et al The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43 (01) 155-63.
• 47 Sebbag M., Simon M., Vincent C. et al The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95 (06) 2672-9.
• 48 Sediva A., Hoza J., Nemcova D. et al Immunological investigation in children with juvenile chronic arthritis. Med Sci Monit 2001; 7 (01) 99-104.
• 49 Shahin AA., Shaker OG., Kamal N. et al. Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography. Rheumatol Int 2002; 22 (02) 84-8.
• 50 Shingu M., Nagai Y., Isayama T. et al The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94 (01) 145-9.
• 51 Simon M., Girbal E., Sebbag M. et al The cytokeratin filament-aggregating protein filaggrin is the target of the so-called „antikeratin antibodies,“ autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993; 92 (03) 1387-93.
• 52 Skoumal M., Kolarz G., Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol 2003; 32 (03) 156-61.
• 53 Soderlin MK., Kastbom A., Kautiainen H. et al Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004; 33 (03) 185-8.
• 54 Thomas L. C-reaktives Protein. In: TH-Books, editor. Labor und Diagnose 2005; 1010-18.
• 55 van Boekel MA., Vossenaar ER., van den Hoogen FH., van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4 (02) 87-93.
• 56 van Leeuwen MA., van Rijswijk MH., Sluiter WJ. et al Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24 (01) 20-7.
• 57 van Schaardenburg D., Hazes JM., de Boer A. et al Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993; 20 (01) 45-52.
• 58 van Schaardenburg D., Lagaay AM., Breedveld FC., Hijmans W., Vandenbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol 1993; 32 (02) 104-9.
• 59 van Schaardenburg D., Lagaay AM., Otten HG., Breedveld FC. The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 1993; 32 (07) 546-9.
• 60 Vingsbo-Lundberg C., Saxne T., Olsson H., Holmdahl R. Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats. Arthritis Rheum 1998; 41 (03) 544-50.
• 61 Visser H., Gelinck LB., Kampfraath AH. et al Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55 (03) 157-61.
• 62 Visser H., Gelinck LB., Kampfraath AH. et al Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55 (03) 157-61.
• 63 Weyand CM., Goronzy JJ. Pathogenesis of rheumatoid arthritis. Med Clin North Am 1997; 81 (01) 29-55.
• 64 Wolbink GJ., Voskuyl AE., Lems WF. et al Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64 (05) 704-7.
• 65 Wollheim FA. Serum markers of articular cartilage damage and repair. Rheum Dis Clin North Am 1999; 25 (02) 417-32 viii
• 66 Wollheim FA. Serum markers of articular cartilage damage and repair. Rheum Dis Clin North Am 1999; 25 (02) 417-32 viii
• 67 Woo P. Cytokines and juvenile idiopathic arthritis. Curr Rheumatol Rep 2002; 4 (06) 452-7.
• 68 Yildirim K., Karatay S., Melikoglu MA. et al Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004; 34 (04) 423-6.
• 69 Yokota S., Miyamae T., Imagawa T. et al Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemiconset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52 (03) 818-25.
• 70 Young BJ., Mallya RK., Leslie RD. et al Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2 6182 97-9.
• 71 Young-Min SA., Cawston TE., Griffiths ID. Markers of joint destruction: principles, problems, and potential. Ann Rheum Dis 2001; 60 (06) 545-8.
• 72 Zendman AJ., Vossenaar ER., van Venrooij WJ. Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004; 37 (04) 295-9.